PRIORITIZING DRUG COMBINATIONS IN CHRONIC B CELL LEUKEMIA BASED ON ANALYSIS OF CELL ADAPTATION TO BCR INHIBITORS IN VIVO

Kód projektu
MUNI/IGA/1200/2021
Období řešení
1/2022 - 12/2022
Investor / Programový rámec / typ projektu
Masarykova univerzita
Fakulta / Pracoviště MU
Lékařská fakulta

We will further decipher the molecular mechanisms of resistance to B-cell receptor (BCR) inhibitors in chronic lymphocytic leukemia (CLL). We will perform in vitro pre-clinical testing of novel therapeutic targets in CLL that could be used in combination with approved BCR inhibitors. We expect our data to help develop a more efficient and time-limited therapy, possibly avoiding toxicity and lowering the risk of resistance development allowed by the long-term treatment with BCR inhibitors.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info